KromaTiD Announces Closing of Series A Round

Fort Collins, CO – June 15th, 2017: KromaTiD ( announces the successful closure of a Series A financing round.

KromaTiD, the provider of Directional Genomic Hybridization and Pinpoint FISH products, successfully completed its Series A round as of May 31st, 2017. Funds from this round will be used to grow sales and expand marketing of KromaTiD’s proprietary products and services, as well as building operations to meet market demand for precision medicine products.

KromaTiD’s Directional Genomic Hybridization and Pinpoint FISH are genomic methods that provide disease researchers and clinicians with unique toolsets for discovering, detecting and diagnosing rearrangements to a person’s genome; data that compliments and expands on existing sequencing and genomic array techniques. KromaTiD’s dGH products and services have been used by NASA, the NIH, biopharmaceutical companies, and institutional research scientists to discover novel genomic rearrangements and to study genomic rearrangements in oncology, rare diseases, radiation biology and chromosomal research.   KromaTiD’s Pinpoint FISH products provide high resolution solutions for detecting known genomic rearrangements that cause many blood cancers and solid tumors. KromaTiD’s technologies also have application in veterinary and agricultural genomic research.

A novel application of KromaTiD’s dGH platform is in detecting off-target effects caused by CRISPR and other techniques being developed to cure certain genetic diseases by directly editing a patient’s genome. As a cell by cell technique with unique capabilities for detecting mis-edits and other low frequency damage to the genome caused by editing, dGH provides gene editing companies with essential data on the fidelity of their systems that they cannot get from any other platform. “This is a very exciting time for KromaTiD and we are delighted to see our platforms providing researchers with essential genomic data that hasn’t been available through any other method,” says Christopher Tompkins, President and General Manager of KromaTiD. “With dGH and Pinpoint FISH, we are making significant impact in the emerging personalized medicine field by complementing our customers next-gen sequencing studies and providing them with a high-resolution routine and robust diagnostic method.”

Development of the dGH and Pinpoint FISH platforms has been previously funded by CSU Ventures, CID4, NASA and angel investors. Commercialization funding through this Series A Round was provided by Colorado and Texas angel investors. “We are very fortunate to have committed investors,” stated Terry Opgenorth, Chair of the KromaTiD Board, “and to have new investors join in supporting commercialization of what promises to be an important set of tools to better understand and diagnose genetic diseases.”

About KromaTiD

KromaTiD, Inc. provides innovative, next-gen cytogenetic products and services focused on discovering, detecting and diagnosing genomic rearrangements in the areas of oncology and rare diseases. Based in Fort Collins Colorado, KromaTiD markets a full suite of dGH and Pinpoint FISH products and services, including custom solutions, tailored to meet individual researchers needs. For more information, please contact us at:

Attack of the (Radioactive) Wild Boars!

KromaTiD is providing assays to Dr. Susan Bailey of Colorado State University and her collaborators at Fukushima University to aid in their project “Improving Radiation Risk Assessment: a case study on wildlife species in Fukushima”. The study is collecting blood samples from the wild boar population surrounding the Fukushima nuclear facility to assess radiation dose and associated biomarkers, to help improve understanding of the health effects of chronic, low dose irradiation of humans and the environment following a nuclear event.

Attack of the (Radioactive) Wild Boars! – Outside

KromaTiD Participates in UnDx Consortium

KromaTiD is one of five companies participating in the UnDx Consortium, with the goal of providing new information to patients with undiagnosed diseases.

KromaTiD Chosen to Present at 2015 Rocky Mountain Life Science Investor and Partnering Conference

Fort Collins, Colorado – September 16, 2015:  KromaTiD, Inc. joins 29 other innovative life science companies from the Rocky Mountain region chosen to present at the 2015 Rocky Mountain Life Science Investor and Partnering Conference (RMLIPC). Representing Arizona, Colorado, Montana, New Mexico and Utah, the companies include emerging and established companies offering groundbreaking pharmaceuticals, medical devices, therapies and technologies.

Read more

Houston…the samples have landed!

NASA Twins Study investigator Susan Bailey, KromaTiD co-founder and Colorado State University Professor, and her team of researchers, Miles McKenna and Lynn Taylor, recently received their first samples from the International Space Station (ISS).  The samples are from NASA astronaut Scott Kelly, who is on the ride of his life; the historic one year mission on the ISS.

Read more

KromaTiD Appoints tebu-bio as European Distributor

FORT COLLINS, CO (PRWeb) (February 9, 2015) – KromaTiD, Inc. is pleased to announce that is partnering with tebu-bio for distribution of its proprietary dGH™ and Pinpoint FISH™ products and services throughout Europe. Headquartered in France, tebu-bio has offices in nine European countries and specializes in supplying innovative life science products and services to the European market. Read more